Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Angiotensin I

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44339   clinical trials with a EudraCT protocol, of which   7369   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    84 result(s) found for: Angiotensin I. Displaying page 5 of 5.
    « Previous 1  2  3  4  5 
    EudraCT Number: 2004-004051-19 Sponsor Protocol Number: IM101-042 Start Date*: 2005-05-13
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Phase IIB, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Abatacept in Combination Therapy with Glucocorticosteroids vs. Placebo plus Gluc...
    Medical condition: SYSTEMIC LUPUS ERYTHEMATOSUS, NOS
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) GB (Prematurely Ended) SE (Prematurely Ended) BE (Completed) AT (Completed) IT (Prematurely Ended)
    Trial results: Removed from public view
    EudraCT Number: 2009-017061-28 Sponsor Protocol Number: D1690C00019 Start Date*: 2010-03-17
    Sponsor Name:AstraZeneca AB
    Full Title: A 24-week, multicentre, randomised, double-blind, age-stratified, placebo controlled phase III study with an 80-week extension period to evaluate the efficacy and safety of dapagliflozin 10 mg once...
    Medical condition: type 2 diabetes mellitus
    Disease: Version SOC Term Classification Code Term Level
    14.1 10027433 - Metabolism and nutrition disorders 10012613 Diabetes mellitus non-insulin-dependent LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Completed) HU (Completed) DE (Completed) AT (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2008-001306-16 Sponsor Protocol Number: CSPP100A2340E1 Start Date*: 2008-06-10
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A 2 year extension to a 36-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of aliskiren on the prevention of left ventricul...
    Medical condition: Essential Hypertension
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Prematurely Ended) SE (Completed) ES (Prematurely Ended) DK (Completed) DE (Prematurely Ended) BE (Completed) HU (Completed) NL (Completed) IT (Prematurely Ended) GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2010-021263-33 Sponsor Protocol Number: 3001101 Start Date*: 2011-05-24
    Sponsor Name:Sykehuset i Vestfold HF
    Full Title: PERIOPERATIVE LEVOSIMENDAN INFUSION IN PATIENTS WITH HEART FAILURE UNDERGOING NON-CARDIAC SURGERY: A PROSPECTIVE, RANDOMISED, PLACEBO-CONTROLLED, DOUBLE-BLIND, MULTICENTER STUDY
    Medical condition: Patients with serious cardiac failure scheduled for non-cardiac surgery
    Disease: Version SOC Term Classification Code Term Level
    14.1 10022117 - Injury, poisoning and procedural complications 10006387 Broken hip LLT
    14.1 10007541 - Cardiac disorders 10007559 Cardiac failure congestive PT
    14.1 10007541 - Cardiac disorders 10007554 Cardiac failure PT
    14.1 10007541 - Cardiac disorders 10066498 Cardiac failure chronic aggravated LLT
    14.1 10007541 - Cardiac disorders 10007558 Cardiac failure chronic PT
    14.1 10007541 - Cardiac disorders 10024102 Left cardiac failure LLT
    14.1 10007541 - Cardiac disorders 10007561 Cardiac failure left LLT
    14.1 10007541 - Cardiac disorders 10007555 Cardiac failure (NOS) LLT
    14.1 10007541 - Cardiac disorders 10007564 Cardiac failure, congestive LLT
    14.1 10007541 - Cardiac disorders 10007562 Cardiac failure NOS LLT
    14.1 10022117 - Injury, poisoning and procedural complications 10020100 Hip fracture PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Prematurely Ended)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5 
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu May 29 19:18:02 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA